BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 24935355)

  • 1. Serum microRNA-210 as a predictive biomarker for treatment response and prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Zhan M; Li Y; Hu B; He X; Huang J; Zhao Y; Fu S; Lu L
    J Vasc Interv Radiol; 2014 Aug; 25(8):1279-1287.e1. PubMed ID: 24935355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with portal vein invasion: safety, efficacy, and prognostic factors.
    Chern MC; Chuang VP; Liang CT; Lin ZH; Kuo TM
    J Vasc Interv Radiol; 2014 Jan; 25(1):32-40. PubMed ID: 24290099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
    Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
    J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified cisplatin-based transcatheter arterial chemoembolization for large hepatocellular carcinoma: multivariate analysis of predictive factors for tumor response and survival in a 163-patient cohort.
    Yoon HM; Kim JH; Kim EJ; Gwon DI; Ko GY; Ko HK
    J Vasc Interv Radiol; 2013 Nov; 24(11):1639-46. PubMed ID: 23962438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma.
    Köberle V; Kronenberger B; Pleli T; Trojan J; Imelmann E; Peveling-Oberhag J; Welker MW; Elhendawy M; Zeuzem S; Piiper A; Waidmann O
    Eur J Cancer; 2013 Nov; 49(16):3442-9. PubMed ID: 23810247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
    Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
    J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
    Niessen C; Unterpaintner E; Goessmann H; Schlitt HJ; Mueller-Schilling M; Wohlgemuth WA; Stroszczynski C; Wiggermann P
    J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.
    Chen R; Gan Y; Ge N; Chen Y; Wang Y; Zhang B; Wang Y; Ye S; Ren Z
    J Vasc Interv Radiol; 2016 Dec; 27(12):1829-1836. PubMed ID: 27553917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
    Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
    J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High expression of serum miR-17-5p associated with poor prognosis in patients with hepatocellular carcinoma.
    Zheng J; Dong P; Gao S; Wang N; Yu F
    Hepatogastroenterology; 2013 May; 60(123):549-52. PubMed ID: 23108086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort.
    Hu HT; Kim JH; Lee LS; Kim KA; Ko GY; Yoon HK; Sung KB; Gwon DI; Shin JH; Song HY
    J Vasc Interv Radiol; 2011 Jul; 22(7):917-23. PubMed ID: 21571545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Modified Model for Assessment for Retreatment with Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients.
    Chen L; Ni CF; Chen SX; Cao JM; Zhu HD; Guo JH; Zhu GY; Zhong BY; Ding W; He SC; Deng G; Teng GJ
    J Vasc Interv Radiol; 2016 Sep; 27(9):1288-1297. PubMed ID: 27013402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.
    Wang Y; Chen Y; Ge N; Zhang L; Xie X; Zhang J; Chen R; Wang Y; Zhang B; Xia J; Gan Y; Ren Z; Ye S
    Ann Surg Oncol; 2012 Oct; 19(11):3540-6. PubMed ID: 22532305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization.
    McNally ME; Martinez A; Khabiri H; Guy G; Michaels AJ; Hanje J; Kirkpatrick R; Bloomston M; Schmidt CR
    Ann Surg Oncol; 2013 Mar; 20(3):923-8. PubMed ID: 22965570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial chemoembolization with additional cisplatin infusion for hepatocellular carcinoma invading the hepatic vein.
    Kim HC; Lee JH; Chung JW; Kang B; Yoon JH; Kim YJ; Lee HS; Jae HJ; Park JH
    J Vasc Interv Radiol; 2013 Feb; 24(2):274-83. PubMed ID: 23369561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
    Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
    J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the Interval between Transarterial Chemoembolization Sessions on Survival in Patients with Unresectable Hepatocellular Carcinoma.
    Kim HD; An J; Kim JH; Gwon DI; Shin JH; Ko GY; Yoon HK; Sung KB; Kim KM; Lee HC
    J Vasc Interv Radiol; 2016 Apr; 27(4):504-13. PubMed ID: 26896049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of chemoembolization for recurrent HCC after curative ablation therapy.
    Okabe N; Morimoto M; Kondo M; Moriya S; Numata K; Maeda S; Tanaka K
    Hepatogastroenterology; 2013 May; 60(123):395-99. PubMed ID: 23108088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies.
    Chen BB; Shih IL; Wu CH; Hsu C; Chen CH; Shih TT; Liu KL; Liang PC
    J Vasc Interv Radiol; 2014 Mar; 25(3):371-8. PubMed ID: 24468045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of serum microRNAs (miR-222, miR-181, miR-216) in human hepatocellular carcinoma and its clinical significance].
    Zhan MX; Li Y; Hu BS; Shao PJ; Meng QW; He X; Huang JW; Lu LG
    Zhonghua Yi Xue Za Zhi; 2013 Jun; 93(23):1830-2. PubMed ID: 24124720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.